Avatrombopag maleate

Avatrombopag maleate is a medication used in the treatment of thrombocytopenia, a condition characterized by low levels of platelets in the blood. It is a second-generation, orally administered thrombopoietin receptor agonist (TPO-RA) that stimulates the production of platelets by the bone marrow.

Mechanism of Action[edit | edit source]

Avatrombopag maleate works by binding to the thrombopoietin receptor, also known as the c-Mpl receptor, on the surface of megakaryocytes in the bone marrow. This binding stimulates the proliferation and differentiation of megakaryocytes, which are the cells responsible for producing platelets. The increased production of platelets helps to alleviate the symptoms of thrombocytopenia.

Uses[edit | edit source]

Avatrombopag maleate is primarily used to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure. It is also used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

Side Effects[edit | edit source]

Common side effects of avatrombopag maleate include headache, fatigue, abdominal pain, and nausea. In rare cases, it can cause serious side effects such as blood clot formation and liver damage.

Dosage and Administration[edit | edit source]

Avatrombopag maleate is taken orally, with the dosage adjusted based on the patient's platelet count and the type of procedure they are scheduled to undergo. It is typically taken once daily for five days prior to the procedure.